Nanocrystal technology for oral delivery of poorly water-soluble drugs

Fabad Journal of Pharmaceutical Sciences

Volumn 34, Issue 1, 2009, Pages 55-65

  Gülsün, Tuǧba ^a   Gürsoy, R Neslihan ^a   Öner, Levent ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bioavailability; Dissolution rate; Nanocrystal; Nanotechnology; Particle size

Indexed keywords

NANOCRYSTAL; RAPAMYCIN; WATER;

BIOAVAILABILITY; DISPERSION; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FILTRATION; FOOD AND DRUG ADMINISTRATION; HUMAN; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACY; PRECIPITATION; REVIEW; SOLUBILITY; SPRAY DRYING;

EID: 79959450158     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Feynman, R. P. (1959). There's plenty of room at the bottom, Caltech. Retrieved September 1, 2002, from http://www.its.caltech.edu/~feynman/plenty. html
2. Zhang L, Webster TJ. Nanotechnology and Nanomaterials: Promises for Improved Tissue Regeneration. Nano Today 4: 66-80, 2009.
3. Chan VSW. Nanomedicine: An Unresolved Regulatory Issue. Regul Toxicol Pharmacol 46: 218-224, 2006. (Pubitemid 44692901)
4. Keck CM, Müller RH. Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Homogenisation. Eur J Pharm and Biopharm 62: 3-16, 2006. (Pubitemid 41736019)
5. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral Bioavailability of Cyclosporine: Solid Lipid Nanoparticles (SLN®) Versus Drug Nanocrystals. Int J Pharm 317: 82-89, 2006. (Pubitemid 43866342)
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3):3-26, 2001. (Pubitemid 33653411)
7. Amidon GL, Lennernäs H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability. Pharm Res 12: 413-420, 1995.
8. Crisp MT, Tucker CJ, Rogers TL, Williams RO, Johnston KP. Turbidimetric Measurement and Prediction of Dissolution Rates of Poorly Soluble Drug Nanocrystals. J Control Release 117: 351-359, 2007. (Pubitemid 46216578)
9. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M. Effect of Particle Size Reduction on Dissolution and Oral Absorption of a Poorly Water-Soluble Drug, Cilostazol, in Beagle Dogs. J Control Release 111: 56-64, 2006. (Pubitemid 43289995)
10. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A Formulation Approach for Poorly-Water-Soluble Compounds. Eur J Pharm Sci 18: 113-120, 2003. (Pubitemid 36184748)
11. Venkatesh, S, Lipper RA. Role of the Development Scientist in Compound Lead Selection and Optimization. J Pharm Sci 89: 145-154, 2000. (Pubitemid 30120795)
12. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J Med Chem 45: 2615-2623, 2002. (Pubitemid 34595232)
13. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm and Biopharm 50: 47-60, 2000. (Pubitemid 30326688)
14. Law D, Wang W, Schmitt AE, Qiu Y, Krill SL, Fort JJ. Properties of Rapidly Dissolving Eutectic Mixtures of Poly(ethylene glycol) and Fenofibrate: The Eutectic Microstructure. J Pharm Sci 92: 505-515, 2003. (Pubitemid 36258965)
15. Serajuddin ATM. Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthroughs. J Pharm Sci 88: 1058-1066, 1999.
16. Pokharkar VB, Mandpe LP, Padamwar MN, Ambike AA, Mahadik KR, Paradkar A. Development, Characterization and Stabilization of Amorphous Form of a Low Tg drug. Powder Tech 167: 20-25, 2006.
17. st ed. İstanbul: Kontrollü Salim Sistemleri Derneǧi; Piksel Bilişim ve Matbaacilik Reklamcilik ve Filmcilik hizmetleri Ltd. Şti.Press; 2004. p. 85-96.
18. st ed. Ankara: Türk Eczacilari Birliǧi Eczacilik Akademisi Yayini, Fersa Matbaacilik Ltd. Şti.Press; 2006. p.1-7.
19. Technology Focus Helping you bring products to market. Serial online: 23 March 2007 Availablefrom: URL: http://www.elan.com/Images/Elan-Technology-07v1- tcm3-17145.pdf
20. Galli C. Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int J Pharm 313: 114-122, 2006.
21. Hovey D, Pruiit J, Ryde T, inventors; Elan Pharma International Limited, assignee. Nanoparticulate megestrol formulations. US patent 7,101,576. 2006 September 5.
22. Liversidge G, Jenkins S, inventors; Elan Pharma International Limited, assignee. Nanoparticulate candesartan formulations. WO 074218. 2006 July 13.
23. Ruddy SB, Ryde NP, inventors; Elan Pharma International Limited, assignee. Solid dose nanoparticulate compositions. WO 666,539. 2002 March 28.
24. Junghanns JUAH, Müller AH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 3(3):295-309, 2008.
25. Müller RH, Keck CM. Challenges and Solutions for the Delivery of Biotech Drugs: a Review of Drug Nanocrystal Technology and Lipid Nanoparticles. J Biotech 113: 151-170, 2004. (Pubitemid 39237077)
26. Möschwitzera JM, Achleitner G, Pomper H, Müller RH. Development of an Intravenously Injectable Chemically Stable Aqueous Omeprazole Formulation Using Nanosuspension Technology. Eur J Pharm and Biopharm 58: 615-619, 2004. (Pubitemid 39297108)
27. Coppola D. Nanocrystal Technology Targets Poorly Water-soluble Drugs. Pharm Tech 27: 20, 2003. (Pubitemid 37392672)
28. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari MF, Fuchs H. Nanomedicine - challenge and perspectives. Angew Chem Int Ed 48: 872-897, 2009.
29. Waard H, Hinrichs WLJ, Frijlink HW. A Novel Bottom-Up Process to Produce Drug Nanocrystals: Controlled Crystallization During Freeze-Drying. J Control Release 128: 179-183, 2008.
30. Kesisoglou F, Panmai S, Wu Y. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59: 631-644, 2007. (Pubitemid 47285408)
31. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3(9):785-796, 2004. (Pubitemid 39242830)
32. Liversidge EM, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18(2):113-120, 2003. (Pubitemid 36184748)
33. Liversidge GG, Conzentino P. Drug Particle Size Reduction for Decreasing Gastric Irritancy and Enhancing Absorption of Naproxen in Rats. Int J Pharm 125: 309-313, 1995.
34. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. DDT 00: 00, 2010.
35. Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 10:845-862, 2008.
36. Suman K, V S R Chandrasekhar P, Balaji S. Drug Nanocrystals: A Novel Formulation Approach for Poorly Soluble Drugs. Int J PharmTech Res 1(3):682-694, 2009.
37. Yamada T, Saito N, Imai T, Otagiri M. Effect of Grinding with Hydroxypropyl Cellulose on the Dissolution and Particle Size of a Poorly Water-Soluble Drug. Chem Pharm Bull 47: 1311-1313, 1999. (Pubitemid 29484889)
38. Kondo N, Iwao T, Masuda H, Yamanoouchi K, Ishihara Y, Yamada N, Haga T, Ogawa Y, Yokoyama K. Improved Oral Absorption of a Poorly Water-Soluble Drug, HO-221, by Wet-Bead Milling Producing Particles in Submicron Region. Chem Pharm Bull 41: 737-740, 1993. (Pubitemid 23166149)
39. Ultrasonic Devices for Liquid Processing. Available from: URL: http://www.hielscher.com/ultrasonics/products.htm
40. Li P, Zhao L. Developing early formulations: Practice and perspective. Int J Pharm 341: 1-19, 2007. (Pubitemid 47088122)
41. Corrigan OI, Crean AM. Comparative Physicochemical Properties of Hydrocortisone / PVP Composites Prepared Using Supercritical Carbon Dioxide by the GAS Anti-Solvent Recrystallization Process, by Coprecipitation and by Spray Drying. Int J Pharm 245: 75-82, 2002. (Pubitemid 35299893)
42. Yin SX, Franchini M, Chen J, Hsieh A, Jen S, Lee T, Hussain M, Smith R. Bioavailability Enhancement of a COX-2 Inhibitor, BMS-347070, from a Nanocrystalline Dispersion Prepared by Spray-Drying. J Pharm Sci 94: 1598-1607, 2005. (Pubitemid 41168688)
43. A. Martin, P. Bustamante, A.H.C. Chun, Interfacial phenomenon, Physical Pharmacy, Lippincott Williams & Wilkins, Maryland, 1993, pp. 362-392.
44. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 62:491-502, 2010.
45. Choi JY, Yoo JY, Kwak HS, Uk Nam B, Lee J. Role of Polymeric Stabilizers for Drug Nanocrystal Dispersions. Curr Appl Phys 5: 472-474, 2005. (Pubitemid 40714976)
46. Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm 370: 202-209, 2009.
47. Mauludin R, Müller RH, Keck CM. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm and Biopharm 36 (4-5): 502-510, 2009.
48. Gülsün T, Gürsoy RN, Öner L. Characterization of nanocrystal formulations which contain poorly water soluble drug, ezetimibe. 7th Central European Symposium on Pharmaceutical Technology & Biodelivery Systems, Ljubljana-Slovenia (2008).
49. th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barcelona- Spain (2008).
50. Gülsün T, Gürsoy RN, Öner L, Improving Dissolution Profile of Ezetimibe, When Variability Becomes an Issue in Drug Development: How to Understand, Predict and Manage?, Verona-İtalia (2008).